Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

FDA to Review Abuse-Deterrent Oxycodone Capsule

Michele B. Kaufman, PharmD, BCGP  |  May 18, 2018

FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

Filed under:Drug Updates Tagged with:adalimumabNSAIDsOxycodoneplaque psoriasistildrakizumab-asmn

Tips & Tools for Dealing with Bad Patient Outcomes

Larry Beresford  |  May 18, 2018

Bad things happen to good rheumatologists—and to their patients—and can have profound personal and professional consequences for the doctor. Sometimes recommended treatments can have predictable, but devastating, side effects. Even if the rheumatologist does everything right according to evidence-based best practice, patients can still have bad outcomes, even die—with resulting feelings of sadness, anger, guilt…

Filed under:Professional Topics Tagged with:burnout

Rheumatology Can Use MACRA to Drive Healthcare Improvements

Terence W. Starz, MD, Theodore Pincus, MD, & Janet Bahr, NP, on behalf of the ARHP Practice Committee  |  May 18, 2018

We have entered the second year of the Medicare Access and CHIP (Children’s Health Insurance Program) Reauthorization Act (MACRA) of 2015. It’s no secret that the costs of medical care—17.1% of the U.S. gross national product compared with 9.8% in Great Britain, 10.7% in Canada and 11.6% in France—have become an overwhelming driver for change….

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:alternative payment models (APMs)APMMACRAMedicare Access and CHIP Reauthorization ActMerit-Based Incentive PaymentMIPS

Opioid Refusals: How to Deal with the Angry or Hostile Patient

Ashley Noisette Green, MD  |  May 18, 2018

In July 2017, Todd A. Graham, MD, a practicing orthopedic surgeon in South Bend, Ind., was fatally shot after getting into a heated dispute with a patient and her husband over a requested opioid prescription.1 The murder of Dr. Graham is a tragic example of the potential dangers of physician-patient disagreements. Rheumatology patients often endure…

Filed under:Drug UpdatesProfessional Topics Tagged with:opioid crisis

Rheumatology Coding Corner Question: Billing for an Inflectra Infusion

From the College  |  May 17, 2018

A 68-year-old female patient returns to the office for a second round of Inflectra (infliximab-dyyb) infusion for her rheumatoid arthritis with rheumatoid factor of multiple joints without organ or systems involvement. She reports pain, stiffness and swelling in her left and right knees and right elbow and rates the pain at a 9 on a…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & CodingINFLECTRA (infliximab-dyyb)

6 Things Endocrinologists Want Rheumatologists to Know

Vanessa Caceres  |  May 17, 2018

In your daily contact with rheumatology patients, you likely come across several who have type 1 or 2 diabetes. Are you doing all you can to maximize their treatment? Most physicians know about the damaging health effects of uncontrolled diabetes. From vision loss to kidney failure to nerve damage, those with diabetes require regular vigilance…

Filed under:Conditions Tagged with:collaborationcommunicationdiabetesinterdisciplinarySteroids

Case Review: MRI Leads to Non-Rheumatic Diagnosis Surprise

Anna Helena Jonsson, MD, PhD, & Julia F. Charles, MD, PhD  |  May 17, 2018

Rheumatologists often rely on magnetic resonance imaging (MRI) in the evaluation of suspected muscular diseases. Here, we describe a case in which unexpected findings on MRI pointed to a diagnosis rarely considered as a mimicker of rheumatologic disease. The Case A 19-year-old man of Middle Eastern descent was admitted to our hospital for evaluation of…

Filed under:Conditions Tagged with:anorexia nervosamagnetic resonance imagingMRI

Case Report: Refractory Calciphylaxis in Lupus

Joey Kim, MD, Navneet Kaur, MD, Phillip Zhang, MD, & Irene Blanco, MD, MS  |  May 17, 2018

Calciphylaxis is a poorly understood and life-threatening ischemic vasculopathy characterized by calcification of the small- and medium-size arteries in the skin, subcutaneous tissue and internal organs, which leads to thrombosis, tissue necrosis and painful skin ulcerations that won’t heal. The disease has a 50–80% mortality rate. Although affected patients typically have end-stage renal disease (ESRD)…

Filed under:Systemic Lupus Erythematosus Tagged with:calciphylaxisconnective tissue diseaseSystemic lupus erythematosus

Researchers Test Belimumab in Scleroderma

Catherine Kolonko  |  May 17, 2018

A yearlong pilot study that evaluated the safety and efficacy of belimumab in a small group of patients with early diffuse systemic sclerosis found no significant difference in the number of adverse events between those treated with the drug and those who received a placebo. Currently, no drugs are approved specifically for the treatment of…

Filed under:Drug UpdatesSystemic Sclerosis Tagged with:belimumabSScSystemic sclerosis

Case Report: Skin-Deep Eosinophils

Case Report: Skin-Deep Eosinophils

Vivek Mehta, MBBS, Sukhraj Singh, MD, Shubhasree Banerjee, MD, & Ruben Peredo-Wende, MD  |  May 17, 2018

Eosinophilia is usually defined as an eosinophil count of more than 500/microL in peripheral blood.1 An eosinophil count of more than 1,500 is referred to as hypereosinophilia (HE); hypereosinophilic syndrome (HES) is defined as HE associated with organ dysfunction attributable to eosinophilia.2 Eosinophilia can occur due to infectious, malignancy, autoimmune or allergic etiologies. However, a…

Filed under:Vasculitis Tagged with:Eosinophiliaeosinophilic disordersscabies

  • « Previous Page
  • 1
  • …
  • 114
  • 115
  • 116
  • 117
  • 118
  • …
  • 245
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences